Institute of Metagenomics and Microbial Technologies (IMMT) is a biotechnology company committed to the discovery of new antibiotics to prevent and cure diseases caused by antibiotic-resistant bacteria. Antibiotic treatment failure of infectious diseases is a serious global public health problem. Already 70% of pathogenic bacteria are resistant to the currently used antibiotics which is associated with increased rates of morbidity and mortality. Each year at least 23,000 people die from an infection in the United States (source CDC) and the number of deaths is even larger in Europe (source WHO).
Ales Lapanje, PhD
Tomaz Rijavec, PhD
Jan Zrimec, PhD
Driven by the belief that our team at the Institute of Metagenomics and Microbial Technologies (IMMT) can make a great contribution to the end of the global problem of antibiotic treatment failure, we put all our knowledge, effort and time into making a significant solution. Our solution is based on the strong fundamental knowledge of environmental molecular microbiology which was gained over more than a decade of scientific and applicative research.
The IMMT's competition builds their antibiotic pipeline mainly by exploiting antibiotics from bacteria that can be cultured in the laboratory, which is approximately 0.01% of all bacterial genera. But IMMT uses a functional metagenomic* approach and can exploit all bacteria, thus it is 10,000 times more efficient at finding new antibiotic compounds than the competition.
*Functional metagenomics - collecting and analyzing microbes' genetic material recovered directly from the environment.
Current antibiotic development is not able to follow the market needs due to the fast occurrence of antibiotic resistant microbes. At IMMT we understand that this is a great business opportunity. Therefore, the most important feature of our solution is to industrialize the functional metagenomic pipeline. IMMT uses not only proven techniques but also innovates the business model.
At the moment we are looking for strategic partners and investors to help us realize our vision of creating a new platform for the discovery of antibiotics that will benefit present and future generations. Please contact us by E: firstname.lastname@example.org or T: +386 (0)41 925 729.
25 July 2016
IMMT and dr. Gunter Festel have agreed not to continue with further cooperation. During the negotiation phase we were not able to reach a compromise for a formal agreement. We want to thank dr. Festel for his contribution and wish him much success with his ongoing business projects and his further career challenges.
26 May 2016
The Institute of Metagenomics and Microbial Technologies (IMMT) is a biotechnology company established in 2014 by Ales Lapanje in Ljubljana, the Slovenian capital. Researching the field of metagenomics, IMMT strives to identify new natural compounds produced by microbes. IMMT has a proven track record in the scientific community with collaborations with renowned academic institutions and technology institutes around the world.
The engagement of Gunter Festel as shareholder and non-executive director strengthens the business development activities and supports future financing rounds of IMMT. Gunter Festel is a successful entrepreneur who has co-founded, as a Founding Angel, more than 10 biotechnology companies in Germany and Switzerland. For example, he was a co-founder and CEO of Butalco, a company developing a technology platform for the production of biofuels and biochemicals which was sold to the French company Lesaffre in 2014. This technology enables biofuel producers to use waste material instead of food to solve the ''food vs. fuel'' dilemma.
IMMT Ltd. is a biotechnology company working in the field of environmental molecular microbiology. Its founders have gained wide experience in analysing the functioning of microbial communities in the last 15 years. The research work was carried out in various environments such as soil, biofilms in marine and alpine regions, hotsprings, glaciers, animal and human microbiome. By working on over 40 research and industrial projects, IMMT founders have developed proprietary technologies for the extraction and processing of information of DNA from bacteria present in native environments. IMMT is aiming to commercialise its technology platform which enables to obtain information coded in DNA from unculturable bacteria. Our The solutions are suitable for the use in industrial and medical applications as well as to develop customised solutions based on this approach.
Contact: Blaz Petric, T: +386 41 966 665, E: email@example.com